Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study.
Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, Acquaviva A, Necchi F, Obiero CW, Martin LB, Bejon P, Njuguna P, Micoli F, Podda A. Kapulu MC, et al. Among authors: martin lb. Front Immunol. 2022 Sep 9;13:971866. doi: 10.3389/fimmu.2022.971866. eCollection 2022. Front Immunol. 2022. PMID: 36203568 Free PMC article. Clinical Trial.
A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country.
Obiero CW, Ndiaye AGW, Sciré AS, Kaunyangi BM, Marchetti E, Gone AM, Schütte LD, Riccucci D, Auerbach J, Saul A, Martin LB, Bejon P, Njuguna P, Podda A. Obiero CW, et al. Among authors: martin lb. Front Immunol. 2017 Dec 22;8:1884. doi: 10.3389/fimmu.2017.01884. eCollection 2017. Front Immunol. 2017. PMID: 29375556 Free PMC article.
Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial.
Launay O, Ndiaye AGW, Conti V, Loulergue P, Sciré AS, Landre AM, Ferruzzi P, Nedjaai N, Schütte LD, Auerbach J, Marchetti E, Saul A, Martin LB, Podda A. Launay O, et al. Among authors: martin lb. Front Immunol. 2019 Mar 8;10:335. doi: 10.3389/fimmu.2019.00335. eCollection 2019. Front Immunol. 2019. PMID: 30906291 Free PMC article. Clinical Trial.
Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension.
Micoli F, Rossi O, Conti V, Launay O, Sciré AS, Aruta MG, Nakakana UN, Marchetti E, Rappuoli R, Saul A, Martin LB, Necchi F, Podda A. Micoli F, et al. Among authors: martin lb. Front Immunol. 2021 May 4;12:671325. doi: 10.3389/fimmu.2021.671325. eCollection 2021. Front Immunol. 2021. PMID: 34017343 Free PMC article. Clinical Trial.
Dissecting in Vitro the Activation of Human Immune Response Induced by Shigella sonnei GMMA.
Tondi S, Clemente B, Esposito C, Sammicheli C, Tavarini S, Martin LB, Rossi O, Micoli F, Bartolini E, Brazzoli M, Ulivieri C, Blohmke CJ, Schiavetti F. Tondi S, et al. Among authors: martin lb. Front Cell Infect Microbiol. 2022 Feb 3;12:767153. doi: 10.3389/fcimb.2022.767153. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35186786 Free PMC article.
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A. Launay O, et al. Among authors: martin lb. EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15. EBioMedicine. 2017. PMID: 28735965 Free PMC article. Clinical Trial.
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults.
Frenck RW Jr, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, Dickey M, Granada JP, Cilio GL, De Ryck I, Necchi F, Suvarnapunya AE, Rossi O, Acquaviva A, Chandrasekaran L, Clarkson KA, Auerbach J, Marchetti E, Kaminski RW, Micoli F, Rappuoli R, Saul A, Martin LB, Podda A. Frenck RW Jr, et al. Among authors: martin lb. EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep. EClinicalMedicine. 2021. PMID: 34430837 Free PMC article.
Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
Citiulo F, Necchi F, Mancini F, Rossi O, Aruta MG, Gasperini G, Alfini R, Rondini S, Micoli F, Rappuoli R, Saul A, Martin LB. Citiulo F, et al. Among authors: martin lb. PLoS Negl Trop Dis. 2021 Oct 13;15(10):e0009826. doi: 10.1371/journal.pntd.0009826. eCollection 2021 Oct. PLoS Negl Trop Dis. 2021. PMID: 34644291 Free PMC article.
Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson KA, Porter CK, Talaat KR, Kapulu MC, Chen WH, Frenck RW Jr, Bourgeois AL, Kaminski RW, Martin LB. Clarkson KA, et al. Among authors: martin lb. Curr Top Microbiol Immunol. 2024;445:257-313. doi: 10.1007/82_2021_248. Curr Top Microbiol Immunol. 2024. PMID: 35616717 Free PMC article. Review.
262 results